Analysts from Jefferies Group recently restated Molina Healthcare Inc.'s buy rating in a research report released on Friday. The company is seen to have a positive growth this year.

After performing well in the previous year, Molina Healthcare Inc. is analyzed to have a potential upside of 29.07 percent from the stock's previous close, according to Jefferies Group's price objective as quoted by MarketBeat.

Recently, Molina Healthcare Inc.'s stocks were recently sold by insider John C. Molina, selling a total of 20,570 in a transaction last Dec. 21, 2015. Each stock was sold at an average price of $60.80, earning a total of $1,250,656. John now owns 104,921 shares in the company, which is valued at $6,379,196.80. The transaction is registered and filed to the Securities and Exchange Commission (SEC).

This comes before another insider, J. Mario Molina, MD, recently sold 10,000 stocks from the firm's shares on Tuesday, Jan. 5, 2016. J. Mario sold each stock at an average price of $60.83, for a total value of $608,300. The transaction was filed to the SEC.

Meanwhile, Zolmax reports that other equities research analysts also issued reports on the healthcare company. According to the publication, Barclays increased their price objective from $72 to $76 and gave the company an equal weight rating last Nov. 2, 2015.

For Leerink Swann, the company also received an increase on price objective from $97 to $105. However, Zacks Investment Research pulled away from its co-analysts, decreasing Molina Healthcare Inc. from a buy to a hold rating last Jan. 4, 2016.

Furthermore, S&P Equity Research also cut theirs from $32 to $30 and set a hold rating on the stock last November. Molina Healthcare Inc., which is known to have been operating in two segments: Health Plans segment and Molina Medicaid Solutions segment, have been rated with a hold rating from seven equities research analysts. Four equities research analysts have also issued a buy rating for the company's stock.

Molina Healthcare Inc.'s stocks have a hold rating and an average price target of $75.58. It's market cap amounts to $3.15 billion and a P/E ratio of 20.37.

The company has performed a one-year low of $49.37 and a one-year high of $82.37. It also has a 50-day moving average price of $59.89 and a 200-day moving average price of $68.31.